Immuneering Corporation (IMRX) P/E Ratio History
Deep ValueTrading at -3.3x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2023–2023
Loading P/E history...
P/E Ratio Analysis
As of June 13, 2026, Immuneering Corporation (IMRX) trades at a price-to-earnings ratio of -3.3x, with a stock price of $4.19 and trailing twelve-month earnings per share of $-1.24.
The current P/E is 1568% below its 5-year average of 0.2x. Over the past five years, IMRX's P/E has ranged from a low of 0.2x to a high of 0.3x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.9x, IMRX trades at a 114% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 183.0x.
Relative to the broader market, IMRX trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our IMRX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
IMRX Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
IMRX P/E vs Peers
Oncology Therapeutics Developers peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 9.2 | - | +68% | |
| $2B | 6.9Lowest | 0.67 | +817% | |
| $13B | 19.1 | 0.37Best | +58% | |
| $8B | 17.9 | - | +1747%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
IMRX Historical P/E Data (2023–2023)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2023 Q4 | Dec 31 2023 | $7.35 | $38.78 | 0.2x | -16% |
| FY2023 Q3 | Sep 30 2023 | $7.68 | $38.83 | 0.2x | -12% |
| FY2023 Q2 | Jun 30 2023 | $10.14 | $38.79 | 0.3x | +16% |
| FY2023 Q1 | Mar 31 2023 | $9.71 | $38.78 | 0.3x | +11% |
Average P/E for displayed period: 0.2x
What if you invested $1,000 in IMRX back in 2023?
Total return with dividends reinvested · 3+ years of data
Calculate ReturnsHow much would $100/month in IMRX be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs IMRX Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationIMRX vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowIMRX — Frequently Asked Questions
Quick answers to the most common questions about buying IMRX stock.
What is IMRX's P/E ratio?
Immuneering Corporation (IMRX) trailing twelve-month P/E ratio is -3.3x, based on TTM diluted EPS of $-1.24. The 5-year average P/E is 0.2x and the historical range spans 0.2x to 0.3x.
Is IMRX stock overvalued or undervalued?
IMRX trades at -3.3x P/E, below its 5-year average of 0.2x. At the 0th percentile of its historical range (0.2x–0.3x), the stock is priced at a discount to its own history.
Is IMRX stock expensive?
No, IMRX is not expensive on a historical basis. The current P/E of -3.3x is below the 5-year average of 0.2x and sits at the 0th percentile of its valuation range.
What is IMRX's historical P/E range?
Over the past 5 years, IMRX's P/E ratio has ranged from 0.2x to 0.3x, with a median of 0.3x and an average of 0.2x. The current P/E of -3.3x places the stock at the 0th percentile of this range. Full historical data spans 2023–2023.
How does IMRX's P/E compare to the S&P 500?
IMRX trades at -3.3x P/E versus the S&P 500 median of 25.1x. The 113% discount to the market suggests lower growth expectations or perceived higher risk.
How does IMRX's valuation compare to Healthcare peers?
Immuneering Corporation P/E of -3.3x compares to the Healthcare sector median of 22.9x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is IMRX's PEG ratio?
IMRX PEG ratio is N/A, based on a P/E of -3.3x and EPS growth of 37.7%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is IMRX's earnings yield?
IMRX earnings yield is N/A, the inverse of its -3.3x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.